About Eledon Pharmaceuticals, Inc.
https://eledon.comEledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.
CEO
David-Alexandre C. Gros
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-10-05 | Reverse | 1:18 |
| 2017-05-11 | Reverse | 1:9 |
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BVF INC/IL
Shares:6.29M
Value:$12.78M
RA CAPITAL MANAGEMENT, L.P.
Shares:3.57M
Value:$7.24M
BLACKROCK, INC.
Shares:3.47M
Value:$7.03M
Summary
Showing Top 3 of 91
About Eledon Pharmaceuticals, Inc.
https://eledon.comEledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.07M ▼ | $-17.46M ▼ | 0% | $-0.23 ▼ | $-17.46M ▲ |
| Q2-2025 | $0 | $24.73M ▲ | $-11.22M ▼ | 0% | $-0.15 ▼ | $-24.73M ▼ |
| Q1-2025 | $0 | $17.96M ▼ | $-6.5M ▲ | 0% | $-0.08 ▲ | $-6.49M ▲ |
| Q4-2024 | $0 | $24.61M ▲ | $-44.62M ▼ | 0% | $-0.75 ▼ | $-44.1M ▼ |
| Q3-2024 | $0 | $20.51M | $76.97M | 0% | $1.05 | $-20.43M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $93.4M ▼ | $129.86M ▼ | $94.5M ▲ | $35.36M ▼ |
| Q2-2025 | $107.57M ▼ | $144.91M ▼ | $38.88M ▼ | $106.03M ▼ |
| Q1-2025 | $124.88M ▼ | $161.31M ▼ | $46.73M ▼ | $114.58M ▼ |
| Q4-2024 | $140.18M ▲ | $177.41M ▲ | $59.27M ▲ | $118.14M ▲ |
| Q3-2024 | $78.19M | $114.58M | $38.52M | $76.06M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.46M ▼ | $-14.48M ▲ | $12.4M ▼ | $0 | $-2.07M ▲ | $-14.48M ▲ |
| Q2-2025 | $-11.22M ▼ | $-17.71M ▼ | $14.96M ▲ | $0 ▼ | $-2.75M ▲ | $-17.71M ▼ |
| Q1-2025 | $-6.5M ▲ | $-16.06M ▲ | $3.89M ▲ | $115K ▼ | $-12.05M ▼ | $-16.06M ▲ |
| Q4-2024 | $-44.62M ▼ | $-18.99M ▼ | $-47.38M ▼ | $80.17M ▲ | $13.8M ▲ | $-18.99M ▼ |
| Q3-2024 | $63.63M | $-11.77M | $-12.8M | $5.28M | $-19.29M | $-11.77M |
CEO
David-Alexandre C. Gros
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-10-05 | Reverse | 1:18 |
| 2017-05-11 | Reverse | 1:9 |
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BVF INC/IL
Shares:6.29M
Value:$12.78M
RA CAPITAL MANAGEMENT, L.P.
Shares:3.57M
Value:$7.24M
BLACKROCK, INC.
Shares:3.47M
Value:$7.03M
Summary
Showing Top 3 of 91